Pluri Inc. (PLUR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pluri Inc. (PLUR) has a cash flow conversion efficiency ratio of 0.347x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.51 Million) by net assets ($-13.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PLUR market cap for the company's overall valuation and market capitalisation.
Pluri Inc. - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Pluri Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pluri Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pluri Inc. ranked by their cash flow conversion efficiency. Explore cash flow quality index of Pluri Inc. to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Volex Plc
LSE:VLX
|
0.107x |
|
HEC Infra Projects Limited
NSE:HECPROJECT
|
0.067x |
|
Tasman Resources Ltd
AU:TAS
|
-0.077x |
|
e-future.Co.Ltd
KQ:134060
|
0.012x |
|
Energys Group Limited Ordinary Shares
NASDAQ:ENGS
|
N/A |
|
Thanasiri Group Public Company Limited
BK:THANA
|
0.024x |
|
GENFLOW BIOSCIENCES PLC
F:WQ5
|
N/A |
|
Vision Sigma
TA:VISN
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Pluri Inc. (2002–2025)
The table below shows the annual cash flow conversion efficiency of Pluri Inc. from 2002 to 2025. View PLUR stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-865.00K | $-18.21 Million | 21.053x | +732.61% |
| 2024-06-30 | $5.42 Million | $-18.02 Million | -3.328x | -122.77% |
| 2023-06-30 | $15.30 Million | $-22.86 Million | -1.494x | -31.73% |
| 2022-06-30 | $32.19 Million | $-36.50 Million | -1.134x | -109.68% |
| 2021-06-30 | $57.15 Million | $-30.91 Million | -0.541x | -15.07% |
| 2020-06-30 | $56.10 Million | $-26.37 Million | -0.470x | +65.18% |
| 2019-06-30 | $21.82 Million | $-29.45 Million | -1.350x | -79.97% |
| 2018-06-30 | $28.51 Million | $-21.38 Million | -0.750x | -4.98% |
| 2017-06-30 | $30.25 Million | $-21.61 Million | -0.714x | -47.17% |
| 2016-06-30 | $38.16 Million | $-18.52 Million | -0.485x | -36.98% |
| 2015-06-30 | $58.14 Million | $-20.61 Million | -0.354x | -15.14% |
| 2014-06-30 | $62.12 Million | $-19.12 Million | -0.308x | -4.74% |
| 2013-06-30 | $57.47 Million | $-16.89 Million | -0.294x | -238.65% |
| 2012-06-30 | $37.74 Million | $-3.27 Million | -0.087x | +34.53% |
| 2011-06-30 | $43.42 Million | $-5.75 Million | -0.133x | +90.24% |
| 2010-06-30 | $3.98 Million | $-5.41 Million | -1.358x | -8.18% |
| 2009-06-30 | $3.39 Million | $-4.26 Million | -1.256x | +35.54% |
| 2008-06-30 | $2.33 Million | $-4.54 Million | -1.948x | -274.03% |
| 2007-06-30 | $5.90 Million | $-3.07 Million | -0.521x | -116.39% |
| 2006-06-30 | $-644.23K | $-2.05 Million | 3.178x | +419.78% |
| 2005-06-30 | $1.80 Million | $-1.79 Million | -0.994x | +76.53% |
| 2004-06-30 | $357.01K | $-1.51 Million | -4.234x | -434.85% |
| 2003-06-30 | $490.42K | $-388.27K | -0.792x | -193.05% |
| 2002-06-30 | $-75.40K | $-64.16K | 0.851x | -- |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, … Read more